I-mab Biopharma US Limited

I-mab Biopharma Co., Ltd.

Feifei Cui

Lei Fang

Zhengyi Wang

Bingshi Guo

Jingwu Zang

Haijuan Gu

Yuanyuan Yang

Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.

Anti-PD-L1 antibody and IL-7 fusions

Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Human PD-L1 antibodies

The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.

Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof

Growing community of inventors

Shanghai, China

Feifei Cui